790 related articles for article (PubMed ID: 24074699)
1. Targeting high-density lipoproteins: update on a promising therapy.
Verdier C; Martinez LO; Ferrières J; Elbaz M; Genoux A; Perret B
Arch Cardiovasc Dis; 2013 Nov; 106(11):601-11. PubMed ID: 24074699
[TBL] [Abstract][Full Text] [Related]
2. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
[TBL] [Abstract][Full Text] [Related]
3. Apolipoprotein A-II is a key regulatory factor of HDL metabolism as appears from studies with transgenic animals and clinical outcomes.
Maïga SF; Kalopissis AD; Chabert M
Biochimie; 2014 Jan; 96():56-66. PubMed ID: 24012775
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of fenofibrate and extended-release niacin on high-density lipoprotein particle size distribution and cholesterol efflux capacity in dyslipidemic patients.
Franceschini G; Favari E; Calabresi L; Simonelli S; Bondioli A; Adorni MP; Zimetti F; Gomaraschi M; Coutant K; Rossomanno S; Niesor EJ; Bernini F; Benghozi R
J Clin Lipidol; 2013; 7(5):414-22. PubMed ID: 24079282
[TBL] [Abstract][Full Text] [Related]
5. Age-associated decrease of high-density lipoprotein-mediated reverse cholesterol transport activity.
Berrougui H; Khalil A
Rejuvenation Res; 2009 Apr; 12(2):117-26. PubMed ID: 19405812
[TBL] [Abstract][Full Text] [Related]
6. Effect of dalcetrapib plus pravastatin on lipoprotein metabolism and high-density lipoprotein composition and function in dyslipidemic patients: results of a phase IIb dose-ranging study.
Ballantyne CM; Miller M; Niesor EJ; Burgess T; Kallend D; Stein EA
Am Heart J; 2012 Mar; 163(3):515-21, 521.e1-3. PubMed ID: 22424025
[TBL] [Abstract][Full Text] [Related]
7. Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus.
Pang J; Chan DC; Hamilton SJ; Tenneti VS; Watts GF; Barrett PH
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):427-32. PubMed ID: 24285582
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic role of niacin in dyslipidemia management.
Boden WE; Sidhu MS; Toth PP
J Cardiovasc Pharmacol Ther; 2014 Mar; 19(2):141-58. PubMed ID: 24363242
[TBL] [Abstract][Full Text] [Related]
9. Lipid effects of peroxisome proliferator-activated receptor-δ agonist GW501516 in subjects with low high-density lipoprotein cholesterol: characteristics of metabolic syndrome.
Olson EJ; Pearce GL; Jones NP; Sprecher DL
Arterioscler Thromb Vasc Biol; 2012 Sep; 32(9):2289-94. PubMed ID: 22814748
[TBL] [Abstract][Full Text] [Related]
10. Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.
Yvan-Charvet L; Kling J; Pagler T; Li H; Hubbard B; Fisher T; Sparrow CP; Taggart AK; Tall AR
Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1430-8. PubMed ID: 20448206
[TBL] [Abstract][Full Text] [Related]
11. Treatment options for low high-density lipoproteins.
Hafiane A; Kellett S; Genest J
Curr Opin Endocrinol Diabetes Obes; 2014 Apr; 21(2):134-9. PubMed ID: 24535232
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of action of niacin.
Kamanna VS; Kashyap ML
Am J Cardiol; 2008 Apr; 101(8A):20B-26B. PubMed ID: 18375237
[TBL] [Abstract][Full Text] [Related]
13. Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport.
El Khoury P; Waldmann E; Huby T; Gall J; Couvert P; Lacorte JM; Chapman J; Frisdal E; Lesnik P; Parhofer KG; Le Goff W; Guerin M
Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):285-94. PubMed ID: 26681758
[TBL] [Abstract][Full Text] [Related]
14. High-density lipoprotein metabolism and reverse cholesterol transport: strategies for raising HDL cholesterol.
Tosheska Trajkovska K; Topuzovska S
Anatol J Cardiol; 2017 Aug; 18(2):149-154. PubMed ID: 28766509
[TBL] [Abstract][Full Text] [Related]
15. Cholesteryl ester transfer protein (CETP) inhibition beyond raising high-density lipoprotein cholesterol levels: pathways by which modulation of CETP activity may alter atherogenesis.
Klerkx AH; El Harchaoui K; van der Steeg WA; Boekholdt SM; Stroes ES; Kastelein JJ; Kuivenhoven JA
Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):706-15. PubMed ID: 16439711
[TBL] [Abstract][Full Text] [Related]
16. From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk.
Shapiro MD; Fazio S
Circ Res; 2016 Feb; 118(4):732-49. PubMed ID: 26892970
[TBL] [Abstract][Full Text] [Related]
17. Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
Masana L; Cabré A; Heras M; Amigó N; Correig X; Martínez-Hervás S; Real JT; Ascaso JF; Quesada H; Julve J; Palomer X; Vázquez-Carrera M; Girona J; Plana N; Blanco-Vaca F
Atherosclerosis; 2015 Feb; 238(2):213-9. PubMed ID: 25528430
[TBL] [Abstract][Full Text] [Related]
18. [Role of HDL in Cholesterol Efflux and Reverse Cholesterol Transport].
Ayaori M
Rinsho Byori; 2016 Jan; 64(1):57-65. PubMed ID: 27192798
[TBL] [Abstract][Full Text] [Related]
19. Restoration of high-density lipoprotein levels by cholesteryl ester transfer protein expression in scavenger receptor class B type I (SR-BI) knockout mice does not normalize pathologies associated with SR-BI deficiency.
Hildebrand RB; Lammers B; Meurs I; Korporaal SJ; De Haan W; Zhao Y; Kruijt JK; Praticò D; Schimmel AW; Holleboom AG; Hoekstra M; Kuivenhoven JA; Van Berkel TJ; Rensen PC; Van Eck M
Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1439-45. PubMed ID: 20431066
[TBL] [Abstract][Full Text] [Related]
20. Niacin Therapy Increases High-Density Lipoprotein Particles and Total Cholesterol Efflux Capacity But Not ABCA1-Specific Cholesterol Efflux in Statin-Treated Subjects.
Ronsein GE; Hutchins PM; Isquith D; Vaisar T; Zhao XQ; Heinecke JW
Arterioscler Thromb Vasc Biol; 2016 Feb; 36(2):404-11. PubMed ID: 26681752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
